Spectranetics to Participate in Canaccord Genuity

COLORADO SPRINGS, Colo., Oct. 30, 2013 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq: SPNC ) today announced that it will be participating in the Canaccord Genuity Medical Technology and Diagnostics Forum on November 14, 2013 in New York.

Spectranetics management is scheduled to present at 8:00 am ET. Interested parties can access the live audio webcasts at http://www.spectranetics.com . Archived presentations will be available on the Web site for 30 days.

About Spectranetics

Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are sold in more than 40 countries and are used to treat arterial blockages in the heart and legs, as well as the removal of pacemaker and defibrillator leads.

The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. In addition, the Company markets aspiration and cardiac laser catheters for the treatment of blockages in the heart.

The Lead Management (LM) product line includes excimer laser sheaths and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads.

For more information, visit www.spectranetics.com .

COMPANY CONTACT The Spectranetics Corporation Guy Childs, Chief Financial Officer (719) 633-8333 INVESTOR CONTACTS Westwicke Partners Lynn Pieper (415) 202-5678